Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2000 Sep;37(9):653–657. doi: 10.1136/jmg.37.9.653

Identification of PTEN mutations in metastatic melanoma specimens

J T Celebi 1, I Shendrik 1, D Silvers 1, M Peacocke 1
PMCID: PMC1734683  PMID: 10978354

Abstract

CONTEXT—PTEN, a tumour suppressor gene located on chromosome 10q23, develops somatic mutations in various tumours and tumour cell lines including brain, endometrium, prostate, breast, kidney, thyroid, liver, and melanoma.
OBJECTIVES—To investigate the mutational profile of this gene further, as well as its role in tumour progression in melanoma.
DESIGN, SETTINGS—We examined 21 metastatic melanoma samples for 10q23 allelic losses and PTEN sequence alterations. Additionally, we screened these samples for mutations in CDKN2A, a gene in which alterations are well documented in primary melanoma as well as in the germline of familial melanoma.
RESULTS—Loss of heterozygosity (LOH) at 10q23 was observed in 33% (7/21) of the samples tested. We identified four sequence alterations in PTEN (19%) and two in CDKN2A (9.5%). Of interest, only one case showed mutations in both genes.
CONCLUSIONS—These data support the notion that PTEN alterations occur in some metastatic melanomas, and that mutation of this gene plays a role in the progression of some forms of melanoma.


Keywords: PTEN; CDKN2A; melanoma

Full Text

The Full Text of this article is available as a PDF (136.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J. G., Jen J., Isaacs W. B., Bova G. S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997 Nov 15;57(22):4997–5000. [PubMed] [Google Scholar]
  2. Dahia P. L., Marsh D. J., Zheng Z., Zedenius J., Komminoth P., Frisk T., Wallin G., Parsons R., Longy M., Larsson C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997 Nov 1;57(21):4710–4713. [PubMed] [Google Scholar]
  3. FitzGerald M. G., Harkin D. P., Silva-Arrieta S., MacDonald D. J., Lucchina L. C., Unsal H., O'Neill E., Koh J., Finkelstein D. M., Isselbacher K. J. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8541–8545. doi: 10.1073/pnas.93.16.8541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep 1;57(17):3660–3663. [PubMed] [Google Scholar]
  5. Healy E., Belgaid C. E., Takata M., Vahlquist A., Rehman I., Rigby H., Rees J. L. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 1996 Feb 1;56(3):589–593. [PubMed] [Google Scholar]
  6. Healy E., Rehman I., Angus B., Rees J. L. Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer. 1995 Feb;12(2):152–156. doi: 10.1002/gcc.2870120211. [DOI] [PubMed] [Google Scholar]
  7. Herbst R. A., Weiss J., Ehnis A., Cavenee W. K., Arden K. C. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res. 1994 Jun 15;54(12):3111–3114. [PubMed] [Google Scholar]
  8. Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A., Ally D. S., Sheahan M. D., Clark W. H., Jr, Tucker M. A., Dracopoli N. C. Germline p16 mutations in familial melanoma. Nat Genet. 1994 Sep;8(1):15–21. doi: 10.1038/ng0994-15. [DOI] [PubMed] [Google Scholar]
  9. Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N. A., Ding W., Hussey C., Tran T., Miki Y., Weaver-Feldhaus J. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994 Sep;8(1):23–26. doi: 10.1038/ng0994-22. [DOI] [PubMed] [Google Scholar]
  10. Li D. M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997 Jun 1;57(11):2124–2129. [PubMed] [Google Scholar]
  11. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  12. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  13. Lynch E. D., Ostermeyer E. A., Lee M. K., Arena J. F., Ji H., Dann J., Swisshelm K., Suchard D., MacLeod P. M., Kvinnsland S. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet. 1997 Dec;61(6):1254–1260. doi: 10.1086/301639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Monzon J., Liu L., Brill H., Goldstein A. M., Tucker M. A., From L., McLaughlin J., Hogg D., Lassam N. J. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998 Mar 26;338(13):879–887. doi: 10.1056/NEJM199803263381305. [DOI] [PubMed] [Google Scholar]
  15. Myers M. P., Pass I., Batty I. H., Van der Kaay J., Stolarov J. P., Hemmings B. A., Wigler M. H., Downes C. P., Tonks N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513–13518. doi: 10.1073/pnas.95.23.13513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Myers M. P., Stolarov J. P., Eng C., Li J., Wang S. I., Wigler M. H., Parsons R., Tonks N. K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052–9057. doi: 10.1073/pnas.94.17.9052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nelen M. R., van Staveren W. C., Peeters E. A., Hassel M. B., Gorlin R. J., Hamm H., Lindboe C. F., Fryns J. P., Sijmons R. H., Woods D. G. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997 Aug;6(8):1383–1387. doi: 10.1093/hmg/6.8.1383. [DOI] [PubMed] [Google Scholar]
  18. Parmiter A. H., Balaban G., Clark W. H., Jr, Nowell P. C. Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet. 1988 Feb;30(2):313–317. doi: 10.1016/0165-4608(88)90200-2. [DOI] [PubMed] [Google Scholar]
  19. Rhei E., Kang L., Bogomolniy F., Federici M. G., Borgen P. I., Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 1997 Sep 1;57(17):3657–3659. [PubMed] [Google Scholar]
  20. Richmond A., Fine R., Murray D., Lawson D. H., Priest J. H. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas. J Invest Dermatol. 1986 Mar;86(3):295–302. doi: 10.1111/1523-1747.ep12285452. [DOI] [PubMed] [Google Scholar]
  21. Risinger J. I., Hayes A. K., Berchuck A., Barrett J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997 Nov 1;57(21):4736–4738. [PubMed] [Google Scholar]
  22. Steck P. A., Ligon A. H., Cheong P., Yung W. K., Pershouse M. A. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer. 1995 Apr;12(4):255–261. doi: 10.1002/gcc.2870120404. [DOI] [PubMed] [Google Scholar]
  23. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  24. Sun H., Lesche R., Li D. M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6199–6204. doi: 10.1073/pnas.96.11.6199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Suzuki H., Freije D., Nusskern D. R., Okami K., Cairns P., Sidransky D., Isaacs W. B., Bova G. S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998 Jan 15;58(2):204–209. [PubMed] [Google Scholar]
  26. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997 Sep 15;57(18):3935–3940. [PubMed] [Google Scholar]
  27. Teng D. H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K. L., Vinson V. L., Gumpper K. L. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997 Dec 1;57(23):5221–5225. [PubMed] [Google Scholar]
  28. Tsao H., Benoit E., Sober A. J., Thiele C., Haluska F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 1998 Jan 1;58(1):109–113. [PubMed] [Google Scholar]
  29. Tsao H., Zhang X., Benoit E., Haluska F. G. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene. 1998 Jul 2;16(26):3397–3402. doi: 10.1038/sj.onc.1201881. [DOI] [PubMed] [Google Scholar]
  30. Tsou H. C., Ping X. L., Xie X. X., Gruener A. C., Zhang H., Nini R., Swisshelm K., Sybert V., Diamond T. M., Sutphen R. The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1. Hum Genet. 1998 Apr;102(4):467–473. doi: 10.1007/s004390050723. [DOI] [PubMed] [Google Scholar]
  31. Tsou H. C., Teng D. H., Ping X. L., Brancolini V., Davis T., Hu R., Xie X. X., Gruener A. C., Schrager C. A., Christiano A. M. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997 Nov;61(5):1036–1043. doi: 10.1086/301607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walker G. J., Palmer J. M., Walters M. K., Hayward N. K. A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer. 1995 Feb;12(2):134–141. doi: 10.1002/gcc.2870120208. [DOI] [PubMed] [Google Scholar]
  33. Wu X., Senechal K., Neshat M. S., Whang Y. E., Sawyers C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15587–15591. doi: 10.1073/pnas.95.26.15587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yao Y. J., Ping X. L., Zhang H., Chen F. F., Lee P. K., Ahsan H., Chen C. J., Lee P. H., Peacocke M., Santella R. M. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene. 1999 May 20;18(20):3181–3185. doi: 10.1038/sj.onc.1202659. [DOI] [PubMed] [Google Scholar]
  35. Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., Dracopoli N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996 Jan;12(1):97–99. doi: 10.1038/ng0196-97. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES